Inbio Ventures
VC Fund
Moscow, Russian Federation
Inbio Ventures is a VC fund in Moscow focused on Biotechnology and Health Care. We are the ambitious team of professionals with comprehensive experience in academic and biopharmaceutical industry, drug discovery and development, venture investments. We are supported by the Advisory Board of internationally recognized KOLs in various therapeutic areas. We are dedicated to investing in breakthrough drug development projectsworldwide.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Inbio Ventures invests in
Stages Inbio Ventures invests in
Countries Inbio Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrei Petrov
|
|||
Investment Focus
Industry
- Biotechnology 6 (67%)
- Health Care 5 (56%)
- Medical 3 (33%)
- Therapeutics 3 (33%)
- Diabetes 1 (11%)
Stage
- Series B 3 (33%)
- Series C 2 (22%)
- Series F 1 (11%)
- Private Equity 1 (11%)
- Post-IPO Equity 1 (11%)
Country
- United States 5 (56%)
- Canada 1 (11%)
- Australia 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Andrei Petrov
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01. | $36M / Series B / Dec 05, 2017 | ||
| Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01. | $70M / Series B / Jan 05, 2017 | ||
| At Avelas Biosciences, their mission is to advance a new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons, leading to improved surgical results and better outcome for patients. | $20M / Series C / Aug 18, 2016 | ||
| TransMedics provides technology and clinical service solutions, service for heart and lung transplant volume, clinical outcomes, and reduce learning curves. | $12.5M / Private Equity / Jul 12, 2016 | ||
| TransMedics provides technology and clinical service solutions, service for heart and lung transplant volume, clinical outcomes, and reduce learning curves. | $51.2M / Series F / May 26, 2016 | ||
| Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina. | $60M / Post-IPO Equity / Mar 15, 2016 | ||
| Protagonist Therapeutics is a biotechnology company dedicated to the discovery of novel peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions. | $40M / Series C / Jul 16, 2015 | ||
| Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential todrivesignificantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. | $56M / Series B / Apr 23, 2015 | ||
| enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expressionlevels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes. | $11.5M / Series B / Jan 26, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Inbio Ventures invest in?
Inbio Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Inbio Ventures?
Public channels for Inbio Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Inbio Ventures?
The team at Inbio Ventures includes Andrei Petrov (Chief Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
